Budget impact analysis of ocriplasmin for the treatment of symptomatic vitreomacular adhesion in the USA.
Publication/Presentation Date
12-1-2018
Abstract
BACKGROUND: Vitreomacular traction (VMT) treatment options include watchful waiting, vitrectomy and intravitreal ocriplasmin injection (Jetrea
MATERIALS & METHODS: VMT prevalence, treatment patterns and disease resolution rates were from literature, a US retinal-specialist survey and the OASIS trial. Medicare payment rates were applied and a national scenario analysis was conducted.
RESULTS: With ocriplasmin available, vitrectomy use and complications-related costs decreased. Budget impact of ocriplasmin to the health plan was US$143,599 over 2 years or US$0.0060 per-member per-month.
CONCLUSION: Ocriplasmin was projected to be minimally cost-additive at US$0.0060 per-member per-month over 2 years.
Volume
7
Issue
12
First Page
1195
Last Page
1207
ISSN
2042-6313
Published In/Presented At
Yu, T. M., Dugel, P. U., Haller, J. A., Kaiser, P. K., & Arnold, R. J. (2018). Budget impact analysis of ocriplasmin for the treatment of symptomatic vitreomacular adhesion in the USA. Journal of comparative effectiveness research, 7(12), 1195–1207. https://doi.org/10.2217/cer-2018-0057
Disciplines
Business Administration, Management, and Operations | Health and Medical Administration | Management Sciences and Quantitative Methods
PubMedID
30350717
Department(s)
Administration and Leadership
Document Type
Article